reports
Immunocore reports first quarter financial results and provides a busi...
Immunocore reports first quarter financial results and provides a business update Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year On track for Phase 3 TEBE-AM trial to complete enrollment in 1H 2026 On track for dose selection in Phase 3 PRISM-MEL-301 trial in 2H 2025 Initial multiple ascending dose data for HIV functional cure candidate presented during oral session at CROI 2025; dose escalation ongoing Cash, cash equivalents and marketable securities...
Immunocore to present at upcoming investor conferences
Immunocore to present at upcoming investor conferences Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 02 April 2025) , a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the following investor conferences in April. Kempen Life Sciences Conference 1x1 and small group m...
Immunocore presents initial multiple ascending dose data for HIV funct...
Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025 Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025 IMC-M113V was well tolerated, with no dose-limiting toxicities Signals of dose-dependent reduction in active reservoir, and viral control after complete antiretroviral treatment interruption in some PLWH Enrollment in MAD portion of the trial continues with higher doses being evaluated (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAIT...
Immunocore to present at upcoming investor conferences
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 03 March 2025) , a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the following investor conferences in March. TD Cowen 45th Annual Healthcare Conference Presentation: Tuesday, March 4, 2025, at 3:10 p.m. EST ...
Immunocore reports fourth quarter and full year 2024 financial results...
Immunocore reports fourth quarter and full year 2024 financial results and provides a business update KIMMTRAK (tebentafusp) Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025 Executing on KIMMTRAK lifecycle management with two Phase 3 trials (TEBE-AM and ATOM) in additional melanoma indications Advancing PRAME portfolio – first patient randomized in Phase 3 PRISM-MEL-301; enrollment continues in Phase 1/2 trial of brenetafusp combinations in ovarian cancer and NSCLC; first patient dosed in Phase 1 trial of IMC-P115C (PRAME-A02-HLE) Fi...
Immunocore to report fourth quarter and full year 2024 financial resul...
Immunocore to report fourth quarter and full year 2024 financial results and host call on February 26, 2025 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 19 February 2025) , a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will report financial results for the fourth quarter and year ended December 31, 2024 on Wednesday, February 26, 2025. Following the announcement, the Company will h...
Adaptimmune Therapeutics Plc: 5 directors
Five Directors at Adaptimmune Therapeutics Plc sold 133,839 shares at between 0.575USD and 0.582USD. The significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's direct...
- Brian Moretta
- Mark Thomas
- Martin Hall
Hardman & Co Monthly: January 2025
Feature article: Hardman & Co Healthcare Index, 2024 – Tough year for Life Sciences By Dr Martin Hall The main function of the HHI is to monitor the performance, and to highlight the attractiveness, of life sciences investments over the long term, and to try to identify those stocks that have disruptive technologies that consistently allow them to outperform both the index and the markets. Many of the 53 constituents of the index are high-risk, with micro-capitalisations and a long way from pro...
AGL ANGLE PLC
DEMG DELTEX MEDICAL GROUP PLC
TSTL TRISTEL PLC
TRX TISSUE REGENIX GROUP
EKF EKF DIAGNOSTICS HOLDINGS
ODX OMEGA DIAGNOSTICS
AVCT AVACTA GROUP
PHP PRIMARY HEALTH PROPERTIES PLC
AGY ALLERGY THERAPEUTICS PLC
ARBB ARBUTHNOT BANKING GROUP
APH ALLIANCE PHARMA PLC
FUM FUTURA MEDICAL PLC
ALNOV NOVACYT SAS
VLG VENTURE LIFE GROUP
RECI REAL ESTATE CREDIT INVESTMENTS
IMM IMMUPHARMA
PRM PROTEOME SCIENCES PLC
ACSO ACCESSO TECHNOLOGY GROUP
GNS GENUS PLC
SUN SURGICAL INNOVATIONS GROUP PLC
AMS ADVANCED MEDICAL SOLUTIONS GROUP PLC
OMG OXFORD METRICS
EAH ECO ANIMAL HEALTH GROUP
JDG JUDGES SCIENTIFIC
VTAS VOLTA FINANCE (GBP)
SDI SDI GROUP
HVO HVIVO
INDV INDIVIOR PLC
VAL VALIRX
FARON FARON PHARMACEUTICALS OY
ONC ONCIMMUNE HOLDINGS
STX SHIELD THERAPEUTICS
CSN CHESNARA PLC
SNG SYNAIRGEN PLC
IPO IP GROUP
HAT H&T GROUP
SCLP SCANCELL HOLDINGS
SYNC SYNCONA
CIR CIRCASSIA GROUP
SPI SPIRE HEALTHCARE GROUP PLC
AGR ASSURA PLC
APAX APAX GLOBAL ALPHA
ICGT ICG ENTERPRISE TRUST
GDR GENEDRIVE
CTEC CONVATEC GROUP PLC
CREO CREO MEDICAL GROUP
SBTX SKINBIOTHERAPEUTICS
A0MXLB NB PRIVATE EQUITY PARTNERS
FAB FUSION ANTIBODIES
IXI IXICO
OXB OXFORD BIOMEDICA PLC
ABDX ABINGDON HEALTH
IMCR IMMUNOCORE HOLDINGS ADS
POLX POLAREAN IMAGING
AREC ARECOR THERAPEUTICS
ONT OXFORD NANOPORE TECHNOLOGIES PLC
SLN SILENCE THERAPEUTICS PLC
SAR SAREUM HOLDINGS PLC
BAI BENEVOLENTAI
4BB 4BASEBIO PLC
TISSUE REGENIX GROUP PLC
Immunocore announces strategic priorities at 43rd Annual J.P. Morgan H...
Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetration Enrolling three Phase 3 trials across multiple melanoma indications – potential data readouts beginning with TEBE-AM in 2026 Enrolling Phase 1/2 trial with brenetafusp combinations in ovarian and lung cancer; ongoing dose escalation with IMC-R117C (PIWIL1) and IMC-P115C (PRAME-A02-HLE) Presenting initial HIV Phase 1 MAD data in the first quarter 2025 Progressing ...
- Martin Hall
Hardman & Co Healthcare Index: 2024 – Tough year for Life Sciences
The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. For the third year running, despite generally good returns in global markets, particularly in the US, performance in 2024 was poor, not helped by the capital-intensive nature of the sector. The HHI fell 17.7% to 398.9, underperforming all its benchmarks – FTSE 100 (+5.7%), FTSE All-Share (5.6%) and the FTSE AIM All-Share Index (-5...
AGL ANGLE PLC
DEMG DELTEX MEDICAL GROUP PLC
TSTL TRISTEL PLC
TRX TISSUE REGENIX GROUP
EKF EKF DIAGNOSTICS HOLDINGS
ODX OMEGA DIAGNOSTICS
AVCT AVACTA GROUP
PHP PRIMARY HEALTH PROPERTIES PLC
AGY ALLERGY THERAPEUTICS PLC
APH ALLIANCE PHARMA PLC
FUM FUTURA MEDICAL PLC
ALNOV NOVACYT SAS
VLG VENTURE LIFE GROUP
IMM IMMUPHARMA
PRM PROTEOME SCIENCES PLC
GNS GENUS PLC
SUN SURGICAL INNOVATIONS GROUP PLC
AMS ADVANCED MEDICAL SOLUTIONS GROUP PLC
OMG OXFORD METRICS
EAH ECO ANIMAL HEALTH GROUP
JDG JUDGES SCIENTIFIC
SDI SDI GROUP
HVO HVIVO
INDV INDIVIOR PLC
VAL VALIRX
FARON FARON PHARMACEUTICALS OY
ONC ONCIMMUNE HOLDINGS
STX SHIELD THERAPEUTICS
SNG SYNAIRGEN PLC
IPO IP GROUP
SCLP SCANCELL HOLDINGS
SYNC SYNCONA
CIR CIRCASSIA GROUP
SPI SPIRE HEALTHCARE GROUP PLC
AGR ASSURA PLC
GDR GENEDRIVE
CTEC CONVATEC GROUP PLC
CREO CREO MEDICAL GROUP
SBTX SKINBIOTHERAPEUTICS
FAB FUSION ANTIBODIES
IXI IXICO
OXB OXFORD BIOMEDICA PLC
TXG 10X GENOMICS INC CLASS A
ABDX ABINGDON HEALTH
IMCR IMMUNOCORE HOLDINGS ADS
POLX POLAREAN IMAGING
AREC ARECOR THERAPEUTICS
ONT OXFORD NANOPORE TECHNOLOGIES PLC
SLN SILENCE THERAPEUTICS PLC
SAR SAREUM HOLDINGS PLC
BAI BENEVOLENTAI
4BB 4BASEBIO PLC
Z29 TISSUE REGENIX GROUP PLC
029 GROUP SE
Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Confer...
Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 6 January 2025) , a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in in a presentation at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, Californ...
Immunocore appoints Travis Coy, previously a Non-Executive Director, a...
Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 02 January 2025) , a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announces tha...
Immunocore announces first patient dosed in the Phase 1 trial of IMC-P...
Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME IMC-P115C (PRAME-HLE-A02) targets the same peptide and has the same CD3 effector and TCR specificity as brenetafusp, and is designed with extended half-life The Phase 1 trial will assess the safety and clinical activity of IMC-P115C in HLA-A*02:01-positive patients w...
Immunocore announces treatment of first patient in the Phase 1/2 trial...
Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers The Phase 1/2 trial will assess the safety and clinical activity of IMC-R117C, as a monotherapy and in combination with standards of care, in patients with advanced cancers expressing PIWIL1 First immunotherapy program to target PIWIL1, a cancer-testis antigen overexpressed in a range of cancers, including colorectal cancer (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 17 December 2024) , a commercial-stage biotechnology company pion...
EORTC and Immunocore announce enrolment of first patient onto the only...
EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma ATOM is the only active Phase 3 trial for adjuvant treatment of uveal melanoma The trial will assess whether adjuvant treatment with tebentafusp can decrease the risk of relapse, compared to observation (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 11 December 2024) The European Organisation for Research and Treatment of Cancer (EORTC), an independent clinical cancer research organization focusing on improving the standards of cancer treatments for pat...
Immunocore announces reimbursement agreement in England for KIMMTRAK▼ ...
Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 03 December 2024) , a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, inf...
Immunocore to present at upcoming investor conferences
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 8 November 2024) , a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the following investor conferences in November. Guggenheim Securities Healthcare Innovation Conference Fireside Chat: Tuesday, November 12, 2024, at 1:00...
Immunocore reports third quarter financial results and provides a busi...
Immunocore reports third quarter financial results and provides a business update Immunocore reports third quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $80.2 million in 3Q 2024, 28% growth over 3Q 2023 Phase 3 trials in cutaneous melanoma ongoing (PRISM-MEL-301 and TEBE-AM); and Phase 3 trial in adjuvant uveal melanoma (ATOM) to start randomizing in 4Q 2024 Presented Phase 1 brenetafusp data in platinum-resistant ovarian cancer patients; ongoing signal detection in metastatic NSCLC will shift initial data release; focus now o...
- Dave Nicoski
- Ross LaDuke
Vermilion Short Shots: Technically Vulnerable Stocks
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
BA BOEING COMPANY (THE)
WOR WORTHINGTON INDUSTRIES INC.
WNC WABASH NATIONAL CORPORATION
WBA WALGREENS BOOTS ALLIANCE INC
VSAT VIASAT INC.
TXT TEXTRON INC.
TMST TIMKENSTEEL CORP
ROK ROCKWELL AUTOMATION INC.
RMBS RAMBUS INC.
POWI POWER INTEGRATIONS INC.
MKSI MKS INSTRUMENTS INC.
DHT DHT HOLDINGS INC.
CVI CVR ENERGY INC.
ARWR ARROWHEAD PHARMACEUTICALS INC.
AAP ADVANCE AUTO PARTS INC.
LPG DORIAN LPG
AIG AMERICAN INTERNATIONAL GROUP INC.
ALV ALLIANZ SE
WFC WALL FINANCIAL CORPORATION
MUR MURPHY OIL CORPORATION
DOO BRP INC.
IIIN INSTEEL INDUSTRIES INC.
ATKR ATKORE INC
COHU COHU INC.
FI FRANK'S INTERNATIONAL NV
MLHR HERMAN MILLER INC.
VSH VISHAY INTERTECHNOLOGY INC.
SCHW CHARLES SCHWAB CORPORATION
HI HILLENBRAND INC.
ICHR ICHOR HOLDINGS LTD.
MATW MATTHEWS INTERNATIONAL CORPORATION CLASS A
CSTM CONSTELLIUM SE CLASS A
STLA STELLANTIS N.V.
IMCR IMMUNOCORE HOLDINGS ADS
MNSO MINISO GROUP HOLDING ADS (N SHARES)
WOLF WOLFSPEED INC
CR CRANE HOLDINGS CO
STM STABILUS SE
CHRD CHORD ENERGY CORPORATION
FRO FRONTLINE PLC
TGI TGI INFRASTRUCTURES LTD
ASAI SENDAS DISTRIBUIDORA SA
Immunocore to present at the 2024 Cantor Global Healthcare Conference
Immunocore to present at the 2024 Cantor Global Healthcare Conference Immunocore to present at the 2024 Cantor Global Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 12 September 2024) , a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the 2024 Cantor Global Healthcare Conference. 2024 Cantor Global Healthcare Conference ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.